Meeting
2023 ASCO Annual Meeting
Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.
Authors
Tamta Makharadze
LTD High Technology Hospital Med Center, Batumi, Georgia
Tamta Makharadze , Ivane Kiladze , Giorgi Dzagnidze , Nino Semionova , Lika Katselashvili , Natia Vekua , Kasi V. Routhu , Prajak J. Barde , Ajit Nair
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT05021900
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1064)
DOI
10.1200/JCO.2023.41.16_suppl.1064
Abstract #
1064
Poster Bd #
285
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Initial results from a phase II study.
First Author: Tamta Makharadze
Poster
2023 ASCO Annual Meeting
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
First Author: Binghe Xu
First Author: Mafalda Oliveira
Poster
2019 ASCO Annual Meeting
Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.
First Author: Geoffrey J Lindeman